OBJECTIVE: To investigate the effect of chronic use of @entity7855 and intracavernous injection (ICI) with trimix in @entity1 not responding to on-demand monotherapy with @entity7855 or ICI with @entity5015 ( @entity5015 ). @entity1 AND METHODS: The study included 40 @entity1 with @entity323 ( @entity323 ), with a mean (SD) age of 50.7 (11.3) years and unresponsive to on-demand @entity7855 or ICI with @entity5015 as monotherapy. They were assessed using the Sexual Health in @entity1 (SHIM)-5 score for @entity323 severity, penile colour Doppler ultrasonography (CDUS) for peak systolic velocity (PSV), end-diastolic velocity (EDV) and resistance index (RI) with an ICI test using 0.25  mL of trimix of @entity3302 , @entity5015 and @entity5521 . @entity251 , prolactin and @entity165 levels were assessed. @entity1 received 25  mg @entity7855 daily for 8 weeks, combined with twice weekly ICI with 0.25  mL of trimix. After treatment, the Erection Hardness Score (EHS), penile CDUS with ICI and @entity323 Inventory of Treatment Satisfaction were assessed. RESULTS: The mean (SD) SHIM-5 score before treatment was 8.3 (0.5) in 15 of the 40 @entity1 and 6.3 (0.4) in 25. Penile haemodynamics were normal in five (13%), showed @entity9085 in five (13%), @entity432 in 26 (65%) and mixed vascular in four (10%). There was an improved SHIM-5 score in 28 (70%) @entity1 , as shown by their haemodynamic values, duration of erection and EHS with therapy, and 66% satisfaction with treatment. Adverse effects ( @entity546 , @entity10 , facial @entity1671 , @entity2210 , nasal congestion, @entity1296 ) were reported in 17 @entity1 (43%). CONCLUSION: Chronic use of trimix plus daily low-dose @entity7855 improved penile haemodynamics in these @entity1 with @entity323 not responding to on-demand phosphodiesterase-5 inhibitors or ICI with @entity5015 monotherapy.

Combined intracavernous vasoactive drugs and @entity7855 in treatment of severe XXXX not responding to on-demand monotherapy.

@entity1 :: ('9606', 'Species') :: ['men', 'Patients', 'patients', 'PATIENTS', 'Men'] @entity1671 :: ('MESH:D005483', 'Disease') :: ['flushing'] @entity323 :: ('MESH:D007172', 'Disease') :: ['erectile dysfunction', 'ED'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['Testosterone'] @entity5521 :: ('MESH:D010646', 'Chemical') :: ['phentolamine'] @entity9085 :: ('MESH:D014715', 'Disease') :: ['arterial insufficiency'] @entity7855 :: ('MESH:C101426', 'Chemical') :: ['sildenafil'] @entity5015 :: ('MESH:D000527', 'Chemical') :: ['prostaglandin-E1', 'PGE1'] @entity3302 :: ('MESH:D010208', 'Chemical') :: ['papaverine'] @entity2210 :: ('MESH:D004415', 'Disease') :: ['dyspepsia'] @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness'] @entity432 :: ('MESH:D001157', 'Disease') :: ['venous occlusive disease'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headache'] @entity546 :: ('MESH:D004414', 'Disease') :: ['penile pain'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity323 :: (MESH:D007172,Disease) :: ['erectile dysfunction']
